| Identification | Back Directory | [Name]
4-Piperidinemethanamine, 1-(5-isoquinolinylsulfonyl)-α-methyl-, (αR)- | [CAS]
1973494-16-4 | [Synonyms]
4-Piperidinemethanamine, 1-(5-isoquinolinylsulfonyl)-α-methyl-, (αR)- | [Molecular Formula]
C16H21N3O2S | [MOL File]
1973494-16-4.mol | [Molecular Weight]
319.42 |
| Hazard Information | Back Directory | [Description]
BA-1049 is a selective ROCK2 inhibitor. | [Uses]
NRL-1049 (BA-1049) is a ROCK2 selective inhibitor (IC50: 0.59?μM and 26?μM for ROCK2 and ROCK1 respectively). NRL-1049 reduces Lysophosphatidic acid induced ROCK activation in endothelial cells. NRL-1049 reduces lesion volume and hemorrhagic transformation in a mouse model of cavernous angiomas. NRL-1049 also preserves the BBB and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice[1]. | [IC 50]
ROCK1: 26 μM (IC50); ROCK2: 0.59 μM (IC50) | [References]
[1] Mulder IA, et al. The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury. J Cereb Blood Flow Metab. 2024 Jun 4:271678X241238845. DOI:10.1177/0271678X241238845 |
|
|